|
GENOUS™ SUCCESS STORY
New Hope for 43-Year-Old Female Patient with HER2-Positive Breast Cancer
A 43-year-old female patient was diagnosed with HER2-positive and ER/PR (estrogen/progesterone receptor) positive grade III invasive breast cancer. Despite undergoing standard treatments including surgery, chemotherapy, radiotherapy, and hormone therapy (Tamoxifen), the cancer recurred and subsequently metastasized.
CHALLENGE
The patient's cancer was so advanced that conventional treatments gave inconsistent results, ultimately leading to unwanted progression of the disease.
PRECISION CANCER SOLUTIONS
The treating physician turned to next-generation sequencing (NGS) and 21 genetic alterations were identified. Faced with such complexity, the physician opted to use the Genomate® service. The Genomate report provided a comprehensive molecular analysis and treatment ranking, resulting in a personalized, targeted treatment plan. With the support of the molecular tumor board – who carefully interpreted the report – the treating physician decided on a treatment plan for the patient based on her personalized molecular profile.
THE RIGHT DRUG. THE FIRST TIME. EVERYTIME
This targeted approach has been remarkably successful. Patients receive a ranking of drugs based on the entire genetic makeup of their tumor, maximizing their chances of being treated with the right drug.
For the treating oncologist, this means:
Higher success rate
Make decisions faster
Limit guesswork and side effects
Give patients the best treatment opportunities
OUTCOMES AND IMPACT OF TARGETED THERAPY